Treatment of idiopathic pulmonary fibrosis
AssigneeVicore Pharma AB
InventorsCarl-Johan Dalsgaard, Rohit Batta
Life of this patent
Estimating the term…
Abstract
According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.
Claims27
A method of treating idiopathic pulmonary fibrosis in a patient having probable usual interstitial pneumonitis as determined by a pattern on an image of the patient's lungs, wherein said method comprises perorally administering to said patient a therapeutically-effective amount of a sodium salt of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butyl-thiophene-2-sulfonamide, wherein said perorally administering is carried out after a minimum of two hours of fasting and fasting is continued for at least one hour after said perorally administering.
Dependencies are inferred from the claim text.